After around 10 years preclinical studies to optimize and evaluate its therapeutic potency, pegaptanib which shows high efficacy in inhibiting VEGF in different models was approved by the FDA for the treatment of AMD in 2004 with dosage of 0.3 mg per eye every 6 weeks administered intravitreally [56]. The gene discussed is VEGFA; the disease is age-related macular degeneration.